Leading position of Ningxia Weiduo Pharmaceutical Co., Ltd.

From June, 5438 to February, 2006, Yongning Roy Industrial Park submitted its own year-end summary to Ningxia Industry: the output of erythromycin and tetracycline hydrochloride produced by Ningxia Qiyuan Pharmaceutical Company, tylosin and vitamin B 12 produced by Ningxia Vito Pharmaceutical Company in the park accounted for more than 30% of the relevant world markets, ranking first in the world.

At the beginning of the company, it mainly produced white capsules and anti-influenza capsules. Two years later, it was found that the Chinese patent medicine market was limited in China, facing fierce competition from domestic pharmaceutical companies, and the external environment was extremely unfavorable. At the same time, the sales of Chinese patent medicines in the international market are not ideal. In this case, Multidimensional Pharmaceuticals adjusted its strategic concept, turned to lead the production of tylosin, a veterinary antibiotic, and strode abroad to directly target the international market.

"The domestic animal husbandry market is scattered, numerous and miscellaneous, and there is no large-scale industrial cluster, while foreign countries are just the opposite." Li Zhongjun, assistant general manager of Vito Pharmaceutical Co., Ltd., said that tylosin was listed as one of the national key varieties and one of the three new veterinary drugs by 1999, with wide application range, good prospects and few competitors. There are no similar large enterprises in the international market, and the energy and climate conditions in Ningxia are also conducive to tylosin fermentation. After considering the above factors, Multidimensional Pharmaceuticals started the project with an annual output of 300 tons of tylosin in 2000, and achieved export in that year, creating a brilliant record of zero tylosin inventory. In 2003, the output was expanded to 800 tons, reaching an annual output of 1 100 tons, and the products were sold to more than 80 countries and regions in the world.

The expansion of the vitamin B 12 project is also due to the consideration of market development. In 2003, Multidimensional Pharmaceutical Company began trial production of vitamin B 12 after investigation, with a designed capacity of 8 tons, ranking first in the world.